Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding

Area of Science:

• Cardiology
• Pharmacology
• Evidence-Based Medicine

Background:

• ST-segment elevation myocardial infarction (STEMI) is increasingly prevalent in elderly populations with high bleeding risk.
• Optimizing antithrombotic therapy in STEMI patients undergoing percutaneous coronary stenting (PCI) with high bleeding risk remains a challenge.
• Current strategies involve intravenous anticoagulants and dual antiplatelet agents.

Purpose of the Study:

• To review antithrombotic drugs and evidence-based medicine for optimal management in STEMI patients undergoing PCI at high risk of bleeding.
• To elucidate the best antithrombotic strategies for this specific patient group.

Main Methods:

• Review of evidence-based medicine and guideline recommendations.
• Analysis of clinical data regarding antithrombotic agents.
• Discussion of ongoing multi-center prospective clinical trials (EVOLVE short DAPT, MASTER DAPT, POEM).

Main Results:

• Bivalirudin is recommended as an optimized intravenous anticoagulant for high-bleeding-risk STEMI patients undergoing PCI.
• Potent dual antiplatelet agents like ticagrelor and prasugrel with aspirin may enhance clinical benefit without increasing bleeding risk.
• Ongoing trials are investigating optimized antithrombotic management for high bleeding risk patients.

Conclusions:

• Antithrombotic management for STEMI patients undergoing PCI with high bleeding risk requires careful consideration of individual patient factors.
• Bivalirudin and specific dual antiplatelet regimens show promise.
• Future clinical trials are expected to provide more definitive guidance.